TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04779151
Drug: Dostarlimab
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Substance: immunoglobulin G4 (IgG4) humanized monoclonal antibody (mAb) that binds with high affinity to PD-1 Manufacturer: Tesaro Inc. Dose: 500 mg every 21 days for the first 4 cycles, followed by 1,000 mg every 42 days cycle (ie, Q6W)
Study: NCT05290337
Drug: zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BTK inhibitor
Study: NCT04779151
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Substance: Inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) Manufacturer: Tesaro Inc. Dose: Flat-fixed dose (if \<77kg or platelets \<150,000 μL: 200mg; if \>/=77kg and platelets \>/= 150,000μL: 300mg)
Study: NCT04968106
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide will be administered by intravenous infusion over 3 days every 3 weeks (9 g/m²) up to 3 cycles
Study: NCT04783545
Drug: VLX-1005
Normalized name: VLX-1005
DrugBank: VLX-1005 (DB18307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VLX-1005 infusion
Study: NCT04767087
Drug: Honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 gm/Kg/day honey
Study: NCT05972018
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectus Sheath Block: Total 60mL: (20mL 1.3% Liposomal bupivacaine + 30mL 0.25% bupivacaine + 10mL NS).(30mL per side)
Study: NCT05972018
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Total 60mLof 0.2% ropivacaine: (60mL of 0.2% ropivacaine (3 vials)
Study: NCT05972018
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectus Sheath Block: Total 60mL: (20mL 1.3% LB + 30mL 0.25% bupivacaine + 10mL NS. 30mL per side)
Study: NCT03998319
Drug: Tenecteplase (1/3 systemic weight based dose)
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg reconstituted to 20mL for intracoronary infusion at 1/3 weight based dose.
Study: NCT06422494
Drug: hyperinsulinaemic hypoglycaemic clamp
Normalized name: CLAMP
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin will be infused at a continuous rate of 60 mU∙m-2 ∙min-1 and glucose 20% will be infused at a variable rate, aiming for stable plasma glucose levels of 5.0 mmol/L. The infusion rate of glucose will be adjusted by plasma glucose levels, measured at 5-minute intervals. After 30 minutes of stable euglycaemia, plasma glucose levels will be allowed to drop gradually to 2.8 mmol/L and will be maintained at this level for 60 minutes. Then, insulin infusion and adrenergic blockade infusions will be stopped. Glucose infusion will be increased and then tapered until stable euglycaemia plasma levels are reached.
Study: NCT06422494
Drug: Propranolol Hydrochloride 1 MG/ML
Normalized name: propranolol hydrochloride 1 MG/ML
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: When euglycaemic level of 5.0mmol/L is achieved we will start the adrenergic blockade which will continue throughout euglycaemia and hypoglycaemia. The participants will be administered a bolus of phentolamine of 70µg/kg followed by a dose of 7.0µg/kg/min continuous infusion and a bolus of propranolol of 14µg/kg followed by a dose of 1.4µg/kg/min.
Study: NCT06422494
Drug: Phentolamine
Normalized name: Phentolamine
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: When euglycaemic level of 5.0mmol/L is achieved we will start the adrenergic blockade which will continue throughout euglycaemia and hypoglycaemia. The participants will be administered a bolus of phentolamine of 70µg/kg followed by a dose of 7.0µg/kg/min continuous infusion and a bolus of propranolol of 14µg/kg followed by a dose of 1.4µg/kg/min.
Study: NCT05806931
Drug: TAS-102, oxaliplatin, irinotecan with bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will be treated with the study drugs until radiological evidence of disease progression or until treatment discontinuation secondary to adverse events. TAS-OX alternating with TAS-IRI (sequential TASOXIRI) with Bevacizumab, in the treatment of mCRC.
Study: NCT05365035
Drug: Cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by Vein (IV)
Study: NCT05365035
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given under the skin; subcutaneous injection (SQ)
Study: NCT05365035
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by PO
Study: NCT05365035
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV or subcutaneous injection (SQ)
Study: NCT05070390
Drug: Enlicitide Chloride
Normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg capsule administered orally
Study: NCT05288166
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT05288166
Drug: Abiraterone
Normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05288166
Drug: Prednisone or Prednisolone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05288166
Drug: Placebo for Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally.
Study: NCT06388031
Drug: Immune checkpoint inhibitor
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice immunotherapy with one of the following every 21 days until disease progression or intolerable toxicity or up to 17 cycles:~* Pembrolizumab 200mg;~* Tislelizumab 200mg;~* Camrelizumab 200mg;~* Toripalimab 240mg.
Study: NCT06123338
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered on an every 3-week dosing schedule
Study: NCT06123338
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab will be administered on an every 3-week dosing schedule
Study: NCT06123338
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin every 3 weeks, +/-7 days
Study: NCT05227131
Drug: Margetuximab
Normalized name: Margetuximab
DrugBank: Margetuximab (DB14967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Margetuximab (15 mg/kg) will be administrated by intravenous infusion on Day 1 of each cycle.
Study: NCT05227131
Drug: Tucatinib
Normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tucatinib (300 mg) will be administrated orally twice daily (every 12 hours) continuously in 21-day cycles.
Study: NCT06283121
Drug: toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy phase: toripalimab 160mg i.v. D1, 3 weeks per cycle.
Study: NCT04917627
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one vial of vancomycin (1000 mg ) powder form.
Study: NCT05454358
Drug: Letrozole 2.5mg
Normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 0.5mg qd po for 2 years after postoperative adjuvant therapy
Study: NCT06461377
Drug: Glucagon-like peptide-1 receptor agonist：Semaglutide
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The GLP-1RA intervention group was given subcutaneous injection of GLP-1RA for 3 months, while the control group was not given GLP-1RA intervention
Study: NCT00037531
Drug: Sirolimus (RAPAMUNE)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT06616220
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the erector spine plane block
Study: NCT06616220
Drug: 0.9%NaCl
Normalized name: triamcinolone acet/0.9%NaCl/PF 40 mg/mL INJECTION VIAL (ML)
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9% NaCl
Study: NCT05259904
Drug: L-citrulline
Normalized name: L-citrulline
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
Study: NCT06274853
Drug: GS-441524
Normalized name: GS-441524
DrugBank: GS-441524 (DB15686)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral GS-441524 capsules
Study: NCT04849013
Drug: Mescaline 100mg
Normalized name: Mescaline
DrugBank: Mescaline (DB19083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: 100mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Study: NCT04849013
Drug: Mescaline 200mg
Normalized name: Mescaline
DrugBank: Mescaline (DB19083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: 200mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Study: NCT04849013
Drug: Mescaline 400mg
Normalized name: Mescaline
DrugBank: Mescaline (DB19083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: 400mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Study: NCT04849013
Drug: Mescaline 800mg
Normalized name: Mescaline
DrugBank: Mescaline (DB19083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: 800mg Mescaline per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Study: NCT04849013
Drug: Mescaline 800mg + Ketanserin 40mg
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: 800mg Mescaline per os, single dose~Other: 40mg Ketanserin per os, single dose
Study: NCT04937829
Drug: BI 1569912
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1569912
Study: NCT06617091
Drug: GRAdHIVNE1 Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a dose ranging study that will allow for simultaneous enrollment of participants in both low and high dose groups.
Study: NCT01469507
Drug: Hyaluronan
Normalized name: hyaluronan
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 weekly injections
Study: NCT05536037
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT05811221
Drug: Esketamine of single injection
Normalized name: esketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single group: give esketamine 0.75 mg/kg at the time of induction
Study: NCT05811221
Drug: Esketamine of Intermittent injection
Normalized name: esketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intermittent group: give esketamine 0.5mg/kg during anesthesia induction, and during the measuring ring esketamine 0.25mg/kg was given again
Study: NCT06446388
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m2, intravenous infusion, D1, up to 8 cycles.
Study: NCT06592222
Drug: Elranatamab
Normalized name: ELRANATAMAB
DrugBank: Elranatamab (DB15395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCMA-CD3 bispecific antibody
Study: NCT06446388
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 administered as IV infusion on D1/D8 of each cycle.
Study: NCT06446388
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m2, intravenous infusion, D1/D8, up to 8 cycles.
Study: NCT06446388
Drug: QL1706
Normalized name: QL1706
DrugBank: QL1706 (DB17562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg, intravenous infusion,D1
Study: NCT06446388
Drug: Chemotherapy drug
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy recommended by guidelines.
Study: NCT04737850
Drug: Hetrombopag
Normalized name: Hetrombopag
DrugBank: Hetrombopag (DB16184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombopoietin receptor agonist
Study: NCT05244018
Drug: Vitamin D3 tablets
Normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 tablets 50,000 IU units
Study: NCT05244018
Drug: Vitamin D tablets
Normalized name: Calcium With Vitamin D Tablets
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D tablets 5000 units as daily requirements
Study: NCT04810156
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1: MMF 500 mg twice a day Day 2: MMF 1000 mg twice a day
Study: NCT04810156
Drug: Solu-Medrol
Normalized name: SOLU-Medrol
DrugBank: Methylprednisolone hemisuccinate (DB14644)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg/day
Study: NCT04810156
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with mixed or cholestatic liver injury pattern will also be administrated peroral UDCA according to weight
Study: NCT05303935
Drug: Quetiapine 50 MG
Normalized name: quetiapine 50 MG
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of 50mg of quetiapine taken at bedtime for one night.
Study: NCT05382156
Drug: Osilodrostat
Normalized name: osilodrostat
DrugBank: Osilodrostat (DB11837)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral administration of Osilodrostat tablets at different doses according to patient's need
Study: NCT04810156
Drug: Prednisone tablet
Normalized name: Prednisone Tablets
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shift from solu-medrol IV to peroral prednisolon. A tapering plan will be performed.
Study: NCT05359068
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 valsartan capsule
Study: NCT05992428
Drug: DA-8010 5mg
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[Part 1\] DA-8010 5mg + Paroxetine 20mg \[Part 2\] DA-8010 5mg + Mirabegron 50mg
Study: NCT05992428
Drug: Paroxetine 20mg
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: \[Part 1\] DA-8010 5mg + Paroxetine 20mg
Study: NCT05992428
Drug: Mirabegron 50mg
Normalized name: MIRABEGRON 50MG SA TAB
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: \[Part 2\] DA-8010 5mg + Mirabegron 50mg
Study: NCT06597019
Drug: Inclisiran
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran (inclisiran sodium 300 mg subcutaneous (s.c.) for participants with body weight ≥23 kg and inclisiran sodium 180 mg s.c. for participants with body weight \<23 kg. The dose level is based on the participant's body weight on Day 1 (for Part 1) and Day 360 (for Part 2), respectively.
Study: NCT04682509
Drug: Glecaprevir/pibrentasvir
Normalized name: GLECAPREVIR/PIBRENTASVIR
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Manufacturer is AbbVie, Inc., North Chicago, IL Mavyret® is commercially available and FDA approved for the treatment of HCV genotype 1, 2, 3, 4, 5, or 6 infection in patients without cirrhosis or with compensated cirrhosis and also for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor. An immediate release bilayer oral tablet containing a fixed-dose combination of 100 mg of glecaprevir and 40 mg of pibrentasvir. The daily dose of glecaprevir/pibrentasvir used will be the standard FDA approved dose: 3 tablets taken once daily (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg).
Study: NCT05824494
Drug: Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab 10mg/kg,every 3 weeks,IV infusion
Study: NCT05824494
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab paclitaxel ≤260mg/m2,every 3 weeks,IV infusion
Study: NCT06424717
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will be administered Avelumab intravenously (IV).
Study: NCT06424717
Drug: Tuvusertib
Normalized name: Tuvusertib
DrugBank: Tuvusertib (DB18790)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered Tuvusertib orally.
Study: NCT05176379
Drug: Fluconazole 150 mg
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single acute 150 mg dose
Study: NCT06366945
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5 on weeks 1, 3, and 6
Study: NCT06366945
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200 mg on weeks 3, 6, and 9;if adjuvant immunotherapy is omitted, Tislelizumab will be administered on weeks 1, 3, 6, 9, 12, 15 after surgery
Study: NCT06366945
Drug: Polymeric Micellar Paclitaxel
Normalized name: Douxo Micellar
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polymeric Micellar Paclitaxel 300mg/mg/m2 on weeks 1, 3 and 6
Study: NCT05151614
Drug: Colchicine 0.5 MG
Normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 0.5 mg tab 1x2 for 1 week then o.5mg tab. 1x1 for another week + the standard therapy ( total duration of colchicine 14 days).
Study: NCT06604117
Drug: Probucol
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who choose this group will receive Probucol in combination with guideline-recommended lipid-lowering therapy. Specifically, participants in this group will take 0.5 grams of Probucol twice daily alongside the conventional lipid-lowering therapy mentioned in Group 1. The combination of Probucol and conventional therapy aims to further improve lipid profile and address atherosclerosis.
Study: NCT06125756
Drug: Low dose KL001
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will be dosed with single dose of KL001 at 2.5x10\^12 vg/kg.
Study: NCT06125756
Drug: Middle dose KL001
Normalized name: WHEAT MIDDLINGS
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be dosed with single dose of KL001 at 5.0x10\^12 vg/kg.
Study: NCT06125756
Drug: High dose KL001
Normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be dosed with single dose of KL001 at 1.0x10\^13 vg/kg.
Study: NCT05927779
Drug: TFX06 tablet
DrugBank: FX06 (DB05685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFX06 tablet taken orally
Study: NCT05004064
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive acalabrutinib 100mg twice daily for up to six 28 day cycles. Patients can receive 100mg once daily for cycle 1, day 1 to day 7, according to the investigator's discretion.
Study: NCT05004064
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patient will receive rituximab 375 mg/m2 IV on day 1 (+/- 3 days) of each cycle, for a maximum of 6 cycles
Study: NCT06557278
Drug: Bavencio
Normalized name: Bavencio
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-PDL1 checkpoint inhibitor
Study: NCT06443255
Drug: Lidocaine 4%
Normalized name: Lidocaine 4% Patch
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 mL of 4% lidocaine
Study: NCT06443255
Drug: Xylometazoline 0.1%
DrugBank: Xylometazoline (DB06694)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mL of xylometazoline 0.1%
Study: NCT05305768
Drug: IncobotulinumtoxinA
Normalized name: incobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Injection of glabellar rhytids
Study: NCT06319248
Drug: Midodrine
Normalized name: Midodrine
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive standard of care for sepsis and 10 mg of Midodrine every 8 hours administered orally or enterally (via nasogastric tube)
Study: NCT06074263
Drug: Dexamethasone 8mg
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 8mg will be taken orally just prior to surgery.
Study: NCT05487755
Drug: Tadalafil 20Mg Oral Tablet
Normalized name: Tadalafil 20mg Oral tablet
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil is a phosphodiesterase type 5 enzyme (PDE5) inhibitor used mainly in erectile dysfunction and pulmonary hypertension by a mechanism involving increase(NO-cGMP-PKG) signaling pathway.(8) Tadalafil is a powerful pleiotropic drug that it can be used in DN as it can target more than pathway involved in pathogenesis of DN include hyperglycemia and endothelial dysfunction through increase (NO-cGMP) signaling pathway as well as hyperlipidemia
Study: NCT05487755
Drug: Pentoxifylline 400 MG Oral Tablet
Normalized name: pentoxifylline 400 MG Oral Tablet
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline is a methyl xanthine derivative, non selective phosphodiesterase enzyme inhibitor used mainly to treat peripheral vascular diseases by improve blood flow
Study: NCT00006143
Drug: Somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no